Typhoid Fever Vaccines - Global Strategic Business Report

The global market for Typhoid Fever Vaccines was estimated at US$430.6 Million in 2024 and is projected to reach US$1.0 Billion by 2030, growing at a CAGR of 15.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Typhoid Fever Vaccines market.

Global 'Typhoid Fever Vaccines' Market - Key Trends & Drivers Summarized

Why Is The Global Fight Against Typhoid Gaining Unprecedented Momentum?

Over the past decade, the fight against typhoid fever has undergone a major transformation, especially due to renewed attention from global health authorities and the development of novel typhoid fever vaccines. The increasing burden of typhoid, particularly in low- and middle-income countries (LMICs), has triggered significant investments in preventive healthcare measures. According to the World Health Organization (WHO), typhoid fever affects between 11-21 million people globally each year, with approximately 128,000 to 161,000 deaths. Vaccines such as Typbar-TCV (Typhoid Conjugate Vaccine) have emerged as critical interventions due to their long-lasting immunity, applicability to younger age groups, and lower risk of adverse effects. What's more, countries like Pakistan and Zimbabwe have rolled out mass immunization campaigns, which have demonstrated both efficacy and cost-efficiency. As water and sanitation improvements alone are insufficient in high-burden regions, governments are integrating vaccine programs into national immunization schedules. Moreover, the expanded support from organizations like Gavi, the Vaccine Alliance, is streamlining the financing and distribution of these vaccines, accelerating adoption in the regions most in need.

How Is Innovation Shaping The Efficacy And Reach Of Typhoid Fever Vaccines?

The evolution of typhoid vaccines from traditional live attenuated or inactivated types to conjugate vaccines has marked a pivotal advancement in terms of coverage, durability, and age-appropriate administration. Traditional vaccines like Ty21a and Vi polysaccharide had limitations in terms of age restriction (usually ineffective in children under 2) and shorter immunity. The new-generation Typhoid Conjugate Vaccines (TCVs), however, can be administered to children as young as 6 months and provide protection for up to 5 years or longer. This development has significant implications for pediatric immunization strategies in endemic regions. Furthermore, global clinical trials are exploring multi-pathogen conjugate vaccines that combine typhoid protection with other enteric diseases, such as paratyphoid and invasive non-typhoidal salmonella (iNTS). These innovations are particularly critical as antimicrobial resistance (AMR) continues to rise in Salmonella Typhi strains, rendering traditional antibiotic therapies less effective. As a result, preventive immunization is gaining traction as the most sustainable approach to typhoid control. Additionally, biotech firms are investing in thermostable formulations to mitigate cold-chain dependency, which remains a challenge in remote or under-resourced settings.

Can Strategic Policies And International Collaborations Bridge The Accessibility Gap?

As the global healthcare ecosystem becomes more interconnected, the role of policy frameworks and cross-border partnerships is proving vital to the proliferation of typhoid fever vaccines. The WHO's prequalification of TCVs has opened the doors for procurement by United Nations agencies, facilitating widespread implementation. Meanwhile, Gavi's financial support for eligible countries has made vaccines affordable and accessible, particularly in sub-Saharan Africa and South Asia. These interventions are complemented by domestic policy reforms where ministries of health are incorporating typhoid vaccines into routine immunization schedules. Moreover, joint efforts among NGOs, health ministries, and international donors are focusing on strengthening surveillance systems, community awareness, and cold-chain infrastructure to ensure seamless distribution. Global initiatives such as the Coalition against Typhoid are also amplifying advocacy and fostering a.

What's Powering The Surge In Demand For Typhoid Vaccines Around The World?

The growth in the typhoid fever vaccines market is driven by several factors that are reshaping public health priorities and advancing immunization coverage globally. Firstly, the rise in multi-drug resistant (MDR) and extensively drug-resistant (XDR) typhoid strains has drastically limited treatment options, positioning vaccines as a primary line of defense. Secondly, a marked increase in urbanization without corresponding improvements in water and sanitation infrastructure in many LMICs has maintained high transmission rates, sustaining demand for preventive solutions. Thirdly, greater political commitment to combat enteric diseases, especially in Asia and Africa, has translated into comprehensive immunization campaigns and increased healthcare budgets. Additionally, improved diagnostic surveillance has enabled better identification of hotspots, allowing targeted vaccine deployment. From a technological standpoint, the development of pediatric-compatible, single-dose TCVs with extended efficacy has simplified immunization logistics and expanded age group eligibility. Moreover, rising health literacy and community engagement in vaccine initiatives have improved public receptivity, reducing vaccine hesitancy. Lastly, the growing presence of global and regional vaccine manufacturers has increased supply chain reliability, fostering a competitive environment that encourages innovation and price reduction two key levers in expanding vaccine accessibility across diverse geographies.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Live Attenuated Vaccine segment, which is expected to reach US$510.0 Million by 2030 with a CAGR of a 16.9%. The Capsular Polysaccharide Vaccine segment is also set to grow at 16.4% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $117.3 Million in 2024, and China, forecasted to grow at an impressive 21.0% CAGR to reach $226.6 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Typhoid Fever Vaccines Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Typhoid Fever Vaccines Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Typhoid Fever Vaccines Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Bavarian Nordic A/S, Bharat Biotech International Ltd., Biological E. Limited, Bio-Med Pvt. Ltd., and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 39 companies featured in this Typhoid Fever Vaccines market report include:

• Bavarian Nordic A/S
• Bharat Biotech International Ltd.
• Biological E. Limited
• Bio-Med Pvt. Ltd.
• Cadila Healthcare Ltd. (Zydus Lifesciences)
• Chiron Behring Vaccines Pvt. Ltd.
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc
• Haffkine Bio-Pharmaceutical Corp. Ltd.
• Incepta Vaccine Ltd.
• Indian Immunologicals Ltd.
• Merck & Co., Inc.
• Panacea Biotec Ltd.
• PaxVax, Inc.
• Pfizer Inc.
• Prokarium Ltd.
• Sanofi Pasteur
• Serum Institute of India Pvt. Ltd.
• Shanta Biotechnics Ltd.
• SK bioscience Co., Ltd.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.